查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1233127

2023-2030 年按类型（简单仿製药、特种仿製药、生物仿製药）、给药途径、产品、应用、分销渠道、地区和细分市场预测的仿製药市场规模、份额和趋势分析报告

Generic Pharmaceuticals Market Size, Share & Trends Analysis Report By Type (Simple Generics, Specialty Generics, Biosimilars), By Route Of Administration, By Product, By Application, By Distribution Channel, By Region & Segment Forecasts, 2023-2030
出版日期: | 出版商: Grand View Research | 英文 220 Pages | 商品交期: 2-10个工作天内

价格

仿製药市场的增长和趋势

Grand View Research, Inc. 的最新研究预测，从 2023 年到 2030 年，全球仿製药市场将以 8.3% 的复合年增长率增长，达到超过 6829 亿美元的增长。

仿製药市场的增长在很大程度上是由即将到期的产品专利推动的，这为仿製药和生物仿製药製造商将其产品推向市场开闢了道路。 例如，2020 年 7 月，Teva Pharmaceutical Industries Ltd. 与 Takeda Pharmaceutical Company Limited 成立了一家合资企业，以製造和商业化专业资产、复杂仿製药和其他管线。 该合资企业有望推动仿製药市场。

此外，政府正在加大推广仿製药的力度，以降低药品总成本，导致关键产品的专利到期。 例如，澳大利亚治疗机构 (TGA) 的目标是为其公民提供负担得起、高效、优质且易于获得的仿製药。 为了支持仿製药，TGA 致力于减少仿製药的监管环境和报销负担，并通过与製造商的国际合作将仿製药推向市场来减少壁垒。 澳大利亚政府的此类举措为市场开闢了新途径。

在美国，每年有数百万美国人使用仿製药进行治疗，仿製药仍然是医疗保健系统的最佳价值，并且通常被称为“患者保护和医疗保健成本”。考虑到最近医疗改革法的製定，如《负担调整法》的出台，我们可以期待仿製药的普及。 特等书 111-148。 法律要求政府规定的处方药承保范围是这些新健康保险计划的一部分。 此类政策的出台可以提高医疗保健的质量和效率，并促进市场增长。

传染性和非传染性疾病的负担不断增加，易患糖尿病和高血压等慢性病的老龄化人口增加，可能对市场增长产生积极影响。 根据发表的文章，截至 2022 年 9 月，全球每年将有大约 1790 万普通公民患有心血管疾病 (CVD)。 结核病、糖尿病、心血管疾病和艾滋病毒等疾病是导致死亡的主要原因。 这些疾病的发病率和流行率不断增加，预计将推动市场。

仿製药市场报告亮点

  • 按类型划分，小分子部分预计到 2022 年将占据最大份额，达到 91.2%，而大分子部分预计将以最快的速度增长。 生物仿製药的批准和采用的增加预计将推动大分子领域的增长。
  • 在给药途径方面，注射剂增长最快，因为生物仿製药正在获得批准。
  • 按应用划分，心血管疾病在 2022 年占市场份额的 18.27%。 这是由于仿製药他汀类药物的最高处方率，以及高疾病负担。
  • 由于投资增加以及製药公司专注于开发高附加值产品，预计特种仿製药将温和增长。 2019年美国FDA批准了110个联合仿製药。
  • 从分销渠道来看，零售药店细分市场将在 2022 年主导市场空间。 世界各地的零售药店连锁店都在投资先进技术，并采取新举措来提高销售额并吸引更多顾客。
  • 到 2022 年，北美将占据大部分市场份额。 积极的政府举措和不断发展的药品报销环境支持持续增长。

内容

第一章调查方法及范围

  • 市场细分
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 全球市场：CAGR 计算
  • 调查假设
  • 二级信息列表
  • 主要信息列表
  • 初步调查分析
    • 市场情景
    • 主要 KoL 回復
  • 目的
  • 缩写列表

第 2 章执行摘要

  • 市场概况
  • 片段快照
  • 竞争快照

第 3 章市场变量、趋势和范围

  • 描绘渗透率和增长前景
  • 监管状况
  • SWOT 分析，按因素（政治和法律、经济、技术）
  • 波特的五力分析
  • 用户视角分析
  • 仿製药市场动态
    • 市场驱动因素分析
      • 生物製品和小分子专利到期
      • 增加 ANDA 批准并推出仿製药
      • 政府为推广仿製药的使用所做的努力
      • 不断增加的疾病负担和不断增长的老年人口
    • 市场製约因素分析
      • 价格压力

第 4 章仿製药市场 - 细分分析，按类型，2018-2030（十亿美元）

  • 仿製药市场：类型差异分析
  • 简单泛型
  • 特殊通用
  • 生物仿製药

第 5 章仿製药市场 - 细分分析，按应用，2018-2030（十亿美元）

  • 仿製药市场：应用变化分析
  • 中枢神经系统疾病
  • 呼吸系统疾病
  • 激素和相关疾病
  • 消化系统疾病
  • 心血管疾病
  • 感染
  • 癌症
  • 糖尿病
  • 其他

第 6 章仿製药市场 - 细分分析，副产品，2018-2030（十亿美元）

  • 仿製药市场：产品差异分析
  • 小分子
  • 聚合物

第 7 章仿製药市场 - 细分分析，按给药途径，2018-2030 年（十亿美元）

  • 仿製药市场：给药途径变化分析
  • 口语
  • 可注射
  • 可吸入
  • 其他

第 8 章仿製药市场 - 细分分析，按分销渠道，2018-2030 年（十亿美元）

  • 仿製药市场：分销渠道变化分析
  • 医院药房
  • 零售药房
  • 在线药店

第 9 章仿製药市场 - 细分分析，按地区，2018-2030（十亿美元）

  • 仿製药市场，按地区划分的市场份额，2022 年和 2030 年
  • 北美
    • SWOT 分析
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT 分析：
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 意大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT 分析：
    • 日本
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 中国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 印度
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架和赎回方案
    • 泰国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架和赎回方案
    • 韩国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架和赎回方案
  • 拉丁美洲
    • SWOT 分析：
    • 巴西
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 墨西哥
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 中东和非洲 (MEA)
    • SWOT 分析：
    • 南非
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 沙特阿拉伯
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 科威特
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景

第 10 章仿製药市场 - 竞争分析

  • 主要市场进入者的近期趋势和影响分析
    • 新产品发布
    • 併购
    • 许可协议
    • 会议和活动
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 主要客户
  • 上市公司
    • 2022 年主要参与者的市场份额分析
    • 企业市场分析
    • 热图分析
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 私人公司
    • 主要初创公司名单
    • 本地网络地图
  • 公司简介
    • Teva Pharmaceutical Industries Ltd
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Viatris Inc.)
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Sun Pharmaceutical Industries Ltd.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • LUPIN
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Novartis AG
      • Company overview
      • Sandoz International GmbH
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Allergan
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • AstraZeneca
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Sawai Pharmaceutical Co., Ltd.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Hikma Pharmaceuticals PLC
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Dr. Reddy's Laboratories Ltd.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Cipla Inc.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Sanofi
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Aurobindo Pharma
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Endo International plc
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
Product Code: GVR-4-68040-031-8

Generic Pharmaceuticals Market Growth & Trends:

The global generic pharmaceuticals market is expected to reach over USD 682.9 billion expanding at a CAGR of 8.3% from 2023 to 2030, according to a new study by Grand View Research, Inc. The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.

Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.

In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.

The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.

Generic Pharmaceuticals Market Report Highlights:

  • The small molecule segment by type held the largest share of 91.2% in 2022 and the large molecule segment is expected to grow at the fastest rate. The increasing approval and uptake of biosimilars is expected to drive the growth of the large molecule segment.
  • Based on the route of administration, the injectable segment is the fastest-growing segment due to the rising approval for biosimilar drugs.
  • By application, cardiovascular diseases dominated the market with a share of 18.27% in 2022, owing to the highest prescription rate of generic statins coupled with a high disease burden.
  • Specialty generics are expected to grow moderately due to increasing investments and the focus of pharmaceutical companies to develop value-added products. In 2019, the U.S. FDA approved 110 complex generics.
  • Based on distribution channel, the retail pharmacy segment dominated the market space in 2022. Retail pharmacy chains across the world are investing in advanced technologies and undertaking new initiatives to improve sales and attract more customers.
  • North America held the majority share in 2022. Favorable government initiatives coupled with an evolving reimbursement landscape for pharmaceutical products support continual growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Primary Research Analysis
    • 1.11.1 Market scenario
    • 1.11.2 Key KoL responses
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Snapshoty

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory Landscape
  • 3.3 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • 3.4 Porter's Five Forces Analysis
  • 3.5 User Perspective Analysis
  • 3.6 Generic Pharmaceuticals Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Patent expiry of biologics and small molecules
      • 3.6.1.2 Increasing ANDA approval and Generic Product Launches
      • 3.6.1.3 Government initiatives to promote usage of generics
      • 3.6.1.4 Increasing Disease Burden and Rising Geriatric Population
    • 3.6.2 Market Restraint Analysis
      • 3.6.2.1 Pricing Pressures

Chapter 4 Generic Pharmaceuticals Market - Segment Analysis, By Type, 2018 - 2030 (USD Billion)

  • 4.1 Generic Pharmaceuticals Market: Type Movement Analysis
  • 4.2 Simple Generics
    • 4.2.1 Simple Generics Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 4.3 Specialty Generics
    • 4.3.1 Specialty Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4 Biosimilars
    • 4.4.1 Biosimilars Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Generic Pharmaceuticals Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)

  • 5.1 Generic Pharmaceuticals Market: Application Movement Analysis
  • 5.2 Central Nervous System Disorders
    • 5.2.1 Central Nervous System Disorders Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.3 Respiratory Diseases
    • 5.3.1 Respiratory Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.4 Hormones and Related Diseases
    • 5.4.1 Hormones and Related Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.5 Gastrointestinal Diseases
    • 5.5.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.6 Cardiovascular Diseases
    • 5.6.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.7 Infectious Diseases
    • 5.7.1 Infectious Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.8 Cancer
    • 5.8.1 Cancer Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.9 Diabetes
    • 5.9.1 Diabetes Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.10 Others
    • 5.10.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 6 Generic Pharmaceuticals Market - Segment Analysis, By Product, 2018 - 2030 (USD Billion)

  • 6.1 Generic Pharmaceuticals Market: Product Movement Analysis
  • 6.2 Small Molecule
    • 6.2.1 Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3 Large Molecule
    • 6.3.1 Large molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Generic Pharmaceuticals Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion)

  • 7.1 Generic Pharmaceuticals Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.3 Injectable
    • 7.3.1 Injectable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.4 Inhalable
    • 7.4.1 Inhalable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.5 Others
    • 7.5.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 8 Generic Pharmaceuticals Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Billion)

  • 8.1 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
  • 8.2 Hospital Pharmacy
    • 8.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 8.3 Retail Pharmacy
    • 8.3.1 Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 8.4 Online Pharmacy
    • 8.4.1 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 9 Generic Pharmaceuticals Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 9.1 Generic Pharmaceuticals Market, Market Share by Region, 2022 & 2030
  • 9.2 North America
    • 9.2.1 SWOT Analysis
      • 9.2.1.1 North America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 U.S. Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 Canada Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2 Europe
    • 9.2.1 SWOT Analysis:
      • 9.2.1.1 Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.2 Germany
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 Germany Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.3 U.K.
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 UK Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.4 France
      • 9.2.4.1 Key Country Dynamics
      • 9.2.4.2 Target Disease Prevalence
      • 9.2.4.3 Competitive Scenario
      • 9.2.4.4 Regulatory Framework
      • 9.2.4.5 Reimbursement Scenario
      • 9.2.4.6 France Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.5 Italy
      • 9.2.5.1 Key Country Dynamics
      • 9.2.5.2 Target Disease Prevalence
      • 9.2.5.3 Competitive Scenario
      • 9.2.5.4 Regulatory Framework
      • 9.2.5.5 Reimbursement Scenario
      • 9.2.5.6 Italy Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.6 Spain
      • 9.2.6.1 Key Country Dynamics
      • 9.2.6.2 Target Disease Prevalence
      • 9.2.6.3 Competitive Scenario
      • 9.2.6.4 Regulatory Framework
      • 9.2.6.5 Reimbursement Scenario
      • 9.2.6.6 Spain Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.7 Denmark
      • 9.2.7.1 Key Country Dynamics
      • 9.2.7.2 Target Disease Prevalence
      • 9.2.7.3 Competitive Scenario
      • 9.2.7.4 Regulatory Framework
      • 9.2.7.5 Reimbursement Scenario
      • 9.2.7.6 Denmark Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.8 Sweden
      • 9.2.8.1 Key Country Dynamics
      • 9.2.8.2 Target Disease Prevalence
      • 9.2.8.3 Competitive Scenario
      • 9.2.8.4 Regulatory Framework
      • 9.2.8.5 Reimbursement Scenario
      • 9.2.8.6 Sweden Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.9 Norway
      • 9.2.9.1 Key Country Dynamics
      • 9.2.9.2 Target Disease Prevalence
      • 9.2.9.3 Competitive Scenario
      • 9.2.9.4 Regulatory Framework
      • 9.2.9.5 Reimbursement Scenario
      • 9.2.9.6 Norway Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.2.9.7 Rest of Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3 Asia Pacific
    • 9.3.1 SWOT Analysis:
      • 9.3.1.1 Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.2 Japan
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 Target Disease Prevalence
      • 9.3.2.3 Competitive Scenario
      • 9.3.2.4 Regulatory Framework
      • 9.3.2.5 Reimbursement Scenario
      • 9.3.2.6 Japan Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.3 China
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Target Disease Prevalence
      • 9.3.3.3 Competitive Scenario
      • 9.3.3.4 Regulatory Framework
      • 9.3.3.5 Reimbursement Scenario
      • 9.3.3.6 China Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.4 India
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 Target Disease Prevalence
      • 9.3.4.3 Competitive Scenario
      • 9.3.4.4 Regulatory Framework
      • 9.3.4.5 Reimbursement Scenario
      • 9.3.4.6 India Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.5 Australia
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Target Disease Prevalence
      • 9.3.5.3 Competitive Scenario
      • 9.3.5.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.5.5 Australia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.6 Thailand
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Target Disease Prevalence
      • 9.3.6.3 Competitive Scenario
      • 9.3.6.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.6.5 Thailand Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.7 South Korea
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Target Disease Prevalence
      • 9.3.7.3 Competitive Scenario
      • 9.3.7.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.7.5 South Korea Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.3.7.6 Rest of Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4 Latin America
    • 9.4.1 SWOT Analysis:
      • 9.4.1.1 Latin America Generic Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 9.4.2 Brazil
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Target Disease Prevalence
      • 9.4.2.3 Competitive Scenario
      • 9.4.2.4 Regulatory Framework
      • 9.4.2.5 Reimbursement Scenario
      • 9.4.2.6 Brazil Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.3 Mexico
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Target Disease Prevalence
      • 9.4.3.3 Competitive Scenario
      • 9.4.3.4 Regulatory Framework
      • 9.4.3.5 Reimbursement Scenario
      • 9.4.3.6 Mexico Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4 Argentina
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Target Disease Prevalence
      • 9.4.4.3 Competitive Scenario
      • 9.4.4.4 Regulatory Framework
      • 9.4.4.5 Reimbursement Scenario
      • 9.4.4.6 Argentina Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.4.4.7 Rest of Latin America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5 Middle East & Africa (MEA)
    • 9.5.1 SWOT Analysis:
      • 9.5.1.1 Middle East & Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.2 South Africa
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Target Disease Prevalence
      • 9.5.2.3 Competitive Scenario
      • 9.5.2.4 Regulatory Framework
      • 9.5.2.5 Reimbursement Scenario
      • 9.5.2.6 South Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.3 Saudi Arabia
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Target Disease Prevalence
      • 9.5.3.3 Competitive Scenario
      • 9.5.3.4 Regulatory Framework
      • 9.5.3.5 Reimbursement Scenario
      • 9.5.3.6 Saudi Arabia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.4 UAE
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Target Disease Prevalence
      • 9.5.4.3 Competitive Scenario
      • 9.5.4.4 Regulatory Framework
      • 9.5.4.5 Reimbursement Scenario
      • 9.5.4.6 UAE Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5 Kuwait
      • 9.5.5.1 Key Country Dynamics
      • 9.5.5.2 Target Disease Prevalence
      • 9.5.5.3 Competitive Scenario
      • 9.5.5.4 Regulatory Framework
      • 9.5.5.5 Reimbursement Scenario
      • 9.5.5.6 Kuwait Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.5.5.7 Rest of MEA Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10 Generic Pharmaceuticals Market - Competitive Analysis

  • 10.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 10.1.1 New Product Launch
    • 10.1.2 Merger and Acquisition
    • 10.1.3 Licensing Agreements
    • 10.1.4 Conferences and Campaigns
  • 10.2 Company Categorization
    • 10.2.1 Innovators
    • 10.2.2 Market Leaders
  • 10.3 Vendor Landscape
    • 10.3.1 List of key distributors and channel partners
    • 10.3.2 Key customers
  • 10.4 Public Companies
    • 10.4.1 Key company market share analysis, 2022
    • 10.4.2 Company market position analysis
    • 10.4.3 Heat map analysis
    • 10.4.4 Competitive Dashboard Analysis
      • 10.4.4.1 Market Differentiators
  • 10.5 Private Companies
    • 10.5.1 List of key emerging companies
    • 10.5.2 Regional Network Map
  • 10.6 Company Profile
    • 10.6.1 Teva Pharmaceutical Industries Ltd
      • 10.6.1.1 Company overview
      • 10.6.1.2 Financial performance
      • 10.6.1.3 Product benchmarking
      • 10.6.1.4 Strategic initiatives
    • 10.6.2 Viatris Inc.)
      • 10.6.2.1 Company overview
      • 10.6.2.2 Financial performance
      • 10.6.2.3 Product benchmarking
      • 10.6.2.4 Strategic initiatives
    • 10.6.3 Sun Pharmaceutical Industries Ltd.
      • 10.6.3.1 Company overview
      • 10.6.3.2 Financial performance
      • 10.6.3.3 Product benchmarking
      • 10.6.3.4 Strategic initiatives
    • 10.6.4 LUPIN
      • 10.6.4.1 Company overview
      • 10.6.4.2 Financial performance
      • 10.6.4.3 Product benchmarking
      • 10.6.4.4 Strategic initiatives
    • 10.6.5 Novartis AG
      • 10.6.5.1 Company overview
      • 10.6.5.2 Sandoz International GmbH
      • 10.6.5.3 Financial performance
      • 10.6.5.4 Product benchmarking
      • 10.6.5.5 Strategic initiatives
    • 10.6.6 Allergan
      • 10.6.6.1 Company overview
      • 10.6.6.2 Financial performance
      • 10.6.6.3 Product benchmarking
      • 10.6.6.4 Strategic initiatives
    • 10.6.7 AstraZeneca
      • 10.6.7.1 Company overview
      • 10.6.7.2 Financial performance
      • 10.6.7.3 Product benchmarking
      • 10.6.7.4 Strategic initiatives
    • 10.6.8 Sawai Pharmaceutical Co., Ltd.
      • 10.6.8.1 Company overview
      • 10.6.8.2 Financial performance
      • 10.6.8.3 Product benchmarking
      • 10.6.8.4 Strategic initiatives
    • 10.6.9 Hikma Pharmaceuticals PLC
      • 10.6.9.1 Company overview
      • 10.6.9.2 Financial performance
      • 10.6.9.3 Product benchmarking
      • 10.6.9.4 Strategic initiatives
    • 10.6.10 Dr. Reddy's Laboratories Ltd.
      • 10.6.10.1 Company overview
      • 10.6.10.2 Financial performance
      • 10.6.10.3 Product benchmarking
      • 10.6.10.4 Strategic initiatives
    • 10.6.11 Cipla Inc.
      • 10.6.11.1 Company overview
      • 10.6.11.2 Financial performance
      • 10.6.11.3 Product benchmarking
      • 10.6.11.4 Strategic initiatives
    • 10.6.12 Sanofi
      • 10.6.12.1 Company overview
      • 10.6.12.2 Financial performance
      • 10.6.12.3 Product benchmarking
      • 10.6.12.4 Strategic initiatives
    • 10.6.13 Aurobindo Pharma
      • 10.6.13.1 Company overview
      • 10.6.13.2 Financial performance
      • 10.6.13.3 Product benchmarking
      • 10.6.13.4 Strategic initiatives
    • 10.6.14 Endo International plc
      • 10.6.14.1 Company overview
      • 10.6.14.2 Financial performance
      • 10.6.14.3 Product benchmarking
      • 10.6.14.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 Regulatory framework
  • Table 4 Patent expiry
  • Table 5 First generic products
  • Table 6 Healthcare expenses on pharmaceuticals
  • Table 7 Complex generic approved by U.S.FDA (2019)
  • Table 8 Prevalence of GERD
  • Table 9 Estimated new cancer case statistics, 2022
  • Table 10 Total Glaucoma Cases (2020)
  • Table 11 First generic oral products approved in 2019
  • Table 12 Leading market players anticipated to witness highest growth
  • Table 13 List of key distributor
  • Table 14 North America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 15 North America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 16 North America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 17 North America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 18 North America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 24 Canada Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 25 Canada Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 26 Canada Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 26 Canada Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 27 Canada Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 28 Europe Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 29 Europe Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 29 Europe Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 30 Europe Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 31 Europe Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 32 U.K. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 33 U.K. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 34 U.K. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 35 U.K. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 36 U.K. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 37 Germany Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 38 Germany Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 39 Germany Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 Germany Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 41 Germany Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 42 Italy Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 Italy Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 44 Italy Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 45 Italy Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 46 Italy Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 France Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 48 France Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 49 France Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 50 France Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 51 France Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 52 Spain Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 53 Spain Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 54 Spain Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 55 Spain Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 56 Spain Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 57 Denmark Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 58 Denmark Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 59 Denmark Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Denmark Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 61 Denmark Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 62 Sweden Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 63 Sweden Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 64 Sweden Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 65 Sweden Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 66 Sweden Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 67 Norway Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 68 Norway Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 69 Norway Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 70 Norway Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 71 Norway Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 72 Asia Pacific Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 73 Asia Pacific Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 74 Asia Pacific Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 77 Japan Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 78 Japan Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 79 Japan Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 80 Japan Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 81 Japan Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 82 China Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 83 China Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 84 China Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 China Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 86 China Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 87 India Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 88 India Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 89 India Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 90 India Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 91 India Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 92 Australia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 93 Australia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 94 Australia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 95 Australia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 96 Australia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 97 South Korea Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 98 South Korea Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 99 South Korea Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 100 South Korea Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 101 South Korea Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 102 Thailand Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 103 Thailand Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 104 Thailand Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 105 Thailand Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 106 Thailand Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 107 Latin America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 108 Latin America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 109 Latin America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 110 Latin America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 111 Latin America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 112 Brazil Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 113 Brazil Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 114 Brazil Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 115 Brazil Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 116 Brazil Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 117 Mexico Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 118 Mexico Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 119 Mexico Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 120 Mexico Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 121 Mexico Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 122 Argentina Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 123 Argentina Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 124 Argentina Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 125 Argentina Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 126 Argentina Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 127 MEA Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 128 MEA Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 129 MEA Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 130 MEA Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 MEA Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 132 South Africa Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 133 South Africa Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 134 South Africa Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 135 South Africa Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 136 South Africa Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 137 Saudi Arabia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 138 Saudi Arabia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 142 UAE Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 143 UAE Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 144 UAE Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 145 UAE Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 146 UAE Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 147 KUWAIT Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 148 KUWAIT Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 149 KUWAIT Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 150 KUWAIT Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 151 KUWAIT Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Generic Pharmaceuticals market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity Flow Analysis
  • Fig. 10 Generic Pharmaceuticals Market Snapshot
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 User Perspective Analysis
  • Fig. 15 Generic Pharmaceuticals Market Driver Impact
  • Fig. 16 Disease burden of non-communicable diseases (in Million), in 2018
  • Fig. 17 Generic Pharmaceuticals Market Restraint Impact
  • Fig. 18 Generic Pharmaceuticals market: Type outlook and key takeaways
  • Fig. 19 Generic Pharmaceuticals market: Type movement analysis
  • Fig. 20 Simple generics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 21 Specialty generics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 22 Biosimilars Market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Generic Pharmaceuticals market: Application outlook and key takeaways
  • Fig. 24 Generic Pharmaceuticals market: Application movement analysis
  • Fig. 25 Central nervous system disorders market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 Hormones and related diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Gastrointestinal diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 31 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 32 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Generic Pharmaceuticals market: Product outlook and key takeaways
  • Fig. 35 Generic Pharmaceuticals market: Product movement analysis
  • Fig. 36 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Generic Pharmaceuticals Market: Route of Administration Outlook and Key Takeaways
  • Fig. 39 Generic Pharmaceuticals market: Route of administration movement analysis
  • Fig. 40 Oral market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 41 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Inhalable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Generic Pharmaceuticals Market: Distribution Channel Outlook and Key Takeaways
  • Fig. 45 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
  • Fig. 46 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional outlook, 2020 & 2030
  • Fig. 51 North America
  • Fig. 52 North America. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 59 U.K.
  • Fig. 60 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 63 France
  • Fig. 64 France market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Spain
  • Fig. 66 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 67 Italy
  • Fig. 68 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 75 Asia-Pacific
  • Fig. 76 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 77 Japan
  • Fig. 78 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 79 China
  • Fig. 80 China market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 81 India
  • Fig. 82 India market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Thailand
  • Fig. 88 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Middle East & Africa
  • Fig. 98 MEA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 107 Market position analysis
  • Fig. 108 Profit margin
  • Fig. 109 Heat map analysis
  • Fig. 110 Market differentiators
  • Fig. 111 Regional Network Map